Methods: Airway hyperreactivity in allergen challenged rIL-15 treated, non-treated mice and IL-15 overexpressed mice were measured by whole body plethysmography and resistance (RI)/compliance (cdyn) by using Aeroneb® Lab nebulizer system. The cytokines levels were measured by performing ELISA analysis.
Results: rIL-15 delivery to the lung in murine model of asthma protects airway hyperreactivity (PENH response), improves airway resistance (RI), compliance (cdyn) and also downregulates the levels of pro-inflammatory cytokines like IL-4, IL-5, IL-13. In addition, we observed that DOX-inducible CC-10-IL-15 bi-transgenic mice were protected from the induction of Aspergillus extract-induced experimental asthma. The 3 weeks DOX exposed allergen challenged IL-15 bi-transgenic mice show significant reduced airway hyperactivity (PENH response) and resistance (RI), pro-inflammatory cytokines like IL-5, IL-13, goblet cell hyperplasia and also collagen accumulation in the lung compared to no DOX treated allergen challenged IL-15 bi-transgenic mice.
Conclusions: Taken together, we first time report that IL-15 immunotherapy may be a novel therapeutic strategy to improve airway obstruction and resistance in food or environmental allergens induced chronic asthma.